Searchable abstracts of presentations at key conferences in oncology

oa0001p034 | (1) | PacRim7

Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer

Milioli Heloisa Helena , Chia Kee Ming , Portman Neil , Yong Aliza , Tarulli Gerald , Selth Luke , Tilley Wayne , Hickey Theresa , Lim Elgene

Steroid hormone receptors (SHR) play a major role in the normal breast development and breast cancer progression. Estrogen receptor (ER) is expressed in approximately 75% of breast cancers, and the majority of these tumours also express the androgen receptor (AR). While ER-directed therapies have been effective in the majority of patients, a significant subset develops resistance and requires alternative treatment approaches. In the endocrine-resistant setting, emerging insigh...

oa0001p043 | (1) | PacRim7

Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer

Portman Neil , Milioli Heloisa , Yong Aliza , Coulson Rhiannon , Alexandrou Sarah , Lam Natasha , Haupt Sue , Haupt Ygal , Caldon C Elizabeth , Lim Elgene

Estrogen Receptor (ER) signalling, upregulation of the cyclin/CDK pathway, and suppression of p53 form a critical axis controlling proliferation of ER positive breast cancer. In this setting, mutation of p53 is relatively rare and suppression of p53 function can be achieved via regulators MDM2 and MDMX. Activation of p53 by inhibition of MDM2 is a promising therapeutic target in p53 wildtype tumours and several drugs are currently in clinical trials. We hypothesised that the M...

oa0001p012 | (1) | PacRim7

Targeting AR in endocrine-resistant breast cancer

Chia KeeMing , Milioli Heloisa , Portman Neil , Laven-Law Geraldine , Coulson Rhiannon , Yong Aliza , Segara Davendra , Parker Andrew , Caldon Catherine E , Deng Niantao , Swarbrick Alexander , Tilley Wayne D , Hickey Theresa E , Lim Elgene

Introduction: Resistance to endocrine therapy is a major clinical problem in estrogen receptor positive (ER+) breast cancer. The androgen receptor (AR) is expressed in ~90% of all primary ER+ breast cancers and high expression of AR is associated with a better patient outcome in this tumours. However, uncertainty surrounding the role of AR in endocrine resistance is reflected in current clinical trials in which both AR agonists and antagonists are being investigated. Here, we ...